Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Glycomic Therapeutics Market Forecast: What Market Value Is Expected By 2030?

The market for glycomic therapeutics has experienced significant expansion lately, projected to climb from $189.51 billion in 2025 to $221.98 billion in 2026, reflecting a compound annual growth rate of 17.1%. This past growth has been fueled by breakthroughs in glycobiology studies, the creation of enzyme therapies, approvals for medications targeting rare conditions, increased financial support for academic research, and the burgeoning production of biologics.

The glycomic therapeutics sector is poised for substantial expansion, projecting a market valuation of $424.67 billion by 2030, driven by a compounded annual growth rate of 17.6%. This anticipated growth trajectory is fueled by several key factors including the increasing embrace of precision medicine, significant advancements in identifying glycan biomarkers, a broadening pipeline of orphan drugs, forward strides in synthetic biology, and amplified investment in pharmaceutical research. During this forecast period, prominent developments expected to shape the market include advancements in developing drugs based on glycans, a heightened emphasis on therapies that modulate the immune system, greater utilization of enzyme replacement treatments, intensified research into rare and metabolic conditions, and the proliferation of synthetic glycan technologies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11894&type=smp

Glycomic Therapeutics Market Expansion Drivers: What Is Shaping Future Growth?

The escalating incidence of diabetes is anticipated to stimulate the expansion of the glycomic therapeutics sector given that diabetes, a persistent health issue impairing the body’s glucose regulation, is marked by discernible glycan modifications linked to insulin resistance and metabolic irregularities, and specific glycan profiles function as diagnostic and prognostic indicators; for example, England observed a rise in recorded type 2 diabetes among adults aged 17 and above, progressing from 6.8% in March 2023 to 7.0% in March 2024 as per GOV.UK data from March 2025, a trend that consequently fuels the glycomic therapeutics market’s growth.

The burgeoning rates of cancer are projected to be a significant catalyst for the glycomic therapeutics market’s advancement, as cancer, defined by aberrant cell proliferation and metastasis, can be addressed by glycomic therapies that selectively engage with particular cell surface glycans to modulate cellular interactions, signaling, and immune responses, thereby potentially impeding tumor progression and augmenting treatment effectiveness; a noteworthy illustration is the American Cancer Society’s report indicating an uptick in estimated new liver cancer diagnoses among US females, rising from 12,660 in 2022 to 13,230 in 2023, underscoring how this increasing cancer burden supports the glycomic therapeutics market’s upward trajectory.

Glycomic Therapeutics Market Segment Landscape: Which Areas Lead Market Development?

The glycomic therapeutics market covered in this report is segmented –

1) By Class: Isolated, Synthetic

2) By Structures: Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins And Heparin Based Glycans, Targeting Glycosphingolipids, Other Structures

3) By Mode Of Action: Inhibits Neuraminidase, Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate, Erythropoietin And Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthase, Interleukin 1, 2 And 3, Beta And Gamma Interferons, Other Mode Of Action

4) By Indications: Thrombosis And Chemoprophylaxis, Anemia, Anti-Adhesive And Anti-Inflammatory, Cataracts, Gaucher’s Disease, Mps-1 And IV, Cancer, Alzheimer’s Disease, Influenza Type A And B, Other Indications

Subsegments:

1) By Isolated: Natural Glycans, Glycan Derivatives, Glycoproteins

2) By Synthetic: Chemically Synthesized Glycans, Recombinant Glycans, Glycopeptides

Glycomic Therapeutics Market Strategic Trends: What Is Defining The Next Phase Of Growth?

In the competitive glycomic therapeutics arena, leading corporations are prioritizing the creation of groundbreaking approaches, exemplified by glyco-immune checkpoint inhibitors, as a strategy to surmount tumor-induced immune suppression and elevate the effectiveness of treatments. These particular inhibitors are engineered to obstruct the immunosuppressive effects of sugar molecules present on malignant cells, thereby empowering the immune system to more effectively identify and combat cancerous growths. A relevant example of this innovation comes from Palleon Pharmaceuticals Inc., a biotechnology firm based in the United States, which disclosed in June 2023 that the initial participant had received treatment in the combination therapy arm of its Phase 1/2 GLIMMER-01 clinical investigation. This study is assessing their primary glyco-immunology agent, E-602, when administered alongside cemiplimab (marketed as Libtayo®) to individuals battling advanced stages of cancer. The trial’s scope includes evaluating E-602 both as a standalone treatment and in conjunction with cemiplimab, with the objectives of determining its safety profile, its impact on physiological processes, and its capacity to combat tumors. E-602 itself represents a novel type of glyco-immune checkpoint inhibitor, engineered to break down immunosuppressive sialoglycans found on both tumor cells and immune cells through enzymatic action, with the ultimate goal of reactivating anti-cancer immune responses.

Glycomic Therapeutics Market Industry Leaders And Market Competition

Major companies operating in the glycomic therapeutics market are F Hoffmann-La Roche Ltd., Sanofi SA, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Merck KGaA, Agilent Technologies Inc., AMS Bio, Shimadzu Corporation, Waters Corporation, Bruker Corporation, BioMarin Pharmaceutical Inc., Bio Techne Corp., Halozyme Therapeutics Inc., Takara Bio Inc., Vector Laboratories, New England Biolabs Inc., Protalix Biotherapeutics Inc., Genovis AB, Ludger Ltd, GlycoMar Limited

Access The Complete Glycomic Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

Glycomic Therapeutics Market Geographic Analysis: Where Is Demand Growing The Fastest?

North America was the largest region in the glycomic therapeutics in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomic therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model